You are here: Home » Companies » News
Business Standard

Pfizer first MNC to get HIV drug patent in India

P B Jayakumar  |  Mumbai 

Name of
drug

Name of
company

Date/place of opposition

Status

Combivir

GSK

30 March 2006
Kolkata

GSK withdraws
appllication

Nevarapine
Hemihydrate

BI

9 May 2006
Delhi

Written response
from BI, opposition
hearing soon.

TDF

Gilead
Science

9 May 2006
Delhi

Gilead licensed the drug to other Indian
generic cos

TD

Gilead
Science

September 2007
Delhi

NA

Atazanavir

Novartis

27 July
Chennai

Abandoned

Ritonavir

Abott

August 2006
Mumbai

NA

Lopinavir

Abott

August 2006
Mumbai

NA

Kaletra
(soft gel)

Abott

August 2006
Mumbai

Abandoned

Amprenavir

GSK

13 July 2006
Delhi

NA

Abacavir

GSK

June 1997
Kolkata

Abandoned

NA: Not available
Source: Delhi Network of Positive People (DNP+)

These were the main reasons cited by the Indian Patent Office for rejecting the patent for the cancer drug Gleevec, which snowballed into a global patent battle between the Swiss drug major Novartis and the Indian government. Leaders with the public interest groups expressed surprise at the decision of the Indian Patent Office. "This is a major development and is a harbinger of the availability and prices of crucial new drugs. We have to evaluate the importance of this drug for HIV patients in India and will decide on the course of action soon," said Leena Menghaney of Medicines Sans Frontiers (MSF), part of the activists

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, December 11 2007. 00:00 IST
RECOMMENDED FOR YOU
.